종목/BRGX
BioRegenx, Inc. develops, manufactures, and sells medical test equipment and science-based nutritional products in the United States and internationally. The company offers Endocalyx Pro, a dietary supplement targeting microvascular capillary health and a range of other supplements under the MyBodyRx brand name; GlycoCheck software; and other health and wellness devices, such as pulsed electro-magnetic field devices, as well as StimaWELL and ReLounge, an electronic muscle stimulation therapy device; and markets hydrogen water products. It also develops TruScan.Ai mobile app/website that integrates additional health indicators; and VitalWellness app, which merge its DNA and epigenetics platform. In addition, the company operates a social media content management platform, including its interactive search engine. Further, it provides DocSun Artificial Intelligence (AI) Engine, which integrates advanced ballistocardiography that detects an individual's heartbeat without touch; photoplethysmography, a method that uses light to track the flow of blood; and distributes wellness devices. The company sells its products through a direct selling channel to health professionals and research organizations. BioRegenx, Inc. is headquartered in Chattanooga, Tennessee.
| 발표일 | 분기 | EPS 예상 | EPS 실제 | Surprise | 매출 실제 | 발표 직후 반응 |
|---|---|---|---|---|---|---|
| 4월 15일 (수) | 2025 Q4 | — | — | — | — | • 0.0% |
| UNH | 유나이티드헬스 | 364B | +8.9% | 75% (3/4) |
| MRK | 머크 | 281B | +16.0% | 100% (4/4) |
애널리스트 의견이 수집되지 않았습니다.